Providence Resources P.l.c. – Operational Update – Frontier Exploration Licence 2/14 – Southern Porcupine Basin
/
Date26 Sep 2017
OPERATIONAL UPDATEFRONTIER EXPLORATION LICENCE 2/14SOUTHERN PORCUPINE BASIN COMPLETION OF 53/6-1 DRILLING PROGRAMME DE-MOBILISATION OF THE STENA ICEMAX DRILLSHIP FROM IRELAND TO LAS PALMAS Dublin and... Read More →
Stillfront Group AB: eRepublik prepares for launch of "War and Peace: Civil War"
/
Date26 Sep 2017
PRESS RELEASE SEPT 26, 2017 eRepublik prepares for launch of “War and Peace: Civil War” eRepublik Labs, one of the Stillfront Group studios, prepares its... Read More →
Identillect Subscriber Growth Continues
/
Date26 Sep 2017
IRVINE, Calif., Sept. 26, 2017 (GLOBE NEWSWIRE) — Identillect Technologies Corp. (the “Company” or “Identillect”) (TSX-V:ID) (OTCQB:IDTLF) (Frankfurt:8ID), a trusted leading provider of SaaS email... Read More →
HP Showcases 3D Printing Momentum Across Europe With New Customers, Partners, and Reference and Experience Centers
/
Date26 Sep 2017
News highlights: New European customers include Danfoss Group, ETH Zurich, Jaguar-Land Rover, KTM and The Manufacturing Technology Center Henkel, a global leader of high impact... Read More →
Stillfront Group AB: eRepublik förbereder lanseringen av "War and Peace: Civil War"
/
Date26 Sep 2017
PRESSMEDDELANDE2017-09-26 eRepublik förbereder lanseringen av “War and Peace: Civil War” eRepublik Labs, en studio inom Stillfront Group, förbereder sitt tredje mobila MMO strategispel, “War and... Read More →
Sandal plc : Trial Launch
/
Date26 Sep 2017
SANDAL PLC (“Sandal” or “the Company”) TRIAL LAUNCH The Directors of Sandal are pleased to announce that the Company has been selected as a supplier... Read More →
Selexis SA and OSE Immunotherapeutics Expand Strategic Alliance to Further Advance OSE’s OSE-172 and OSE-703 Cancer Immunotherapy Programs
/
Date26 Sep 2017
Second and Third Commercial License Agreements Between the Partners Underscore the Advantages of Selexis’ SUREtechnology Platform™, Aids OSE Immunotherapeutics Candidates’ Advancement into Clinic GENEVA and NANTES,... Read More →
Selexis SA and OSE Immunotherapeutics Expand Strategic Alliance to Further Advance OSE’s OSE-172 and OSE-703 Cancer Immunotherapy Programs
/
Date26 Sep 2017
Second and Third Commercial License Agreements Between the Partners Underscore the Advantages of Selexis’ SUREtechnology Platform™, Aids OSE Immunotherapeutics Candidates’ Advancement into Clinic GENEVA and NANTES,... Read More →
Athenex, Inc.宣佈用於治療日光性角化症的KX-01軟膏第III期臨床試驗招募到首名患者
/
Date26 Sep 2017
紐約水牛城, Sept. 26, 2017 (GLOBE NEWSWIRE) — Athenex, Inc. (Nasdaq:ATNX) 是一間全球性的生物醫藥公司,致力於發掘、研發及商業化治療癌症和相關疾病的新型療法。Athenex, Inc.今日宣佈,治療日光性角化症的KX-01軟膏第III期兩次臨床試驗的其中一次已招募到首名患者。KX-01亦稱為KX2-391,是Athenex產品組合中的創新分子產品。KX-01具有多重作用機轉,包括抑制Src激酶活性及微管蛋白聚合。在臨床前研究中,該化合物對各種癌細胞類型以及角質細胞呈現廣泛的抗增殖活性。 日光性角化症是常見的皮膚病,在美國有4,000萬名患者,特徵是接觸陽光部位出現鱗片狀的硬皮斑塊,其中10至15%的病例在未經治療下會演變為癌症。KX-01的早期臨床試驗結果反映極佳的活性及較理想的不良事件狀況,相比日光性角化症局部治療現行標準的歷史數據,嚴重局部皮膚反應的發生頻率大幅下降。KX-01第二期研究的數據已經提交予2018年舉行的大型皮膚病學會議。 Athenex的臨床開發副總裁David Cutler博士表示:「治療日光性角化症的KX-01軟膏第III期關鍵研究招募到首名患者,是本公司的重要發展里程碑。」 Athenex首席醫療官Rudolf Kwan博士補充:「KX-01軟膏有機會改變日光性角化症局部療法的範式」。 KX-01第III期研究計劃包括兩次雙盲空白對照的隨機試驗,總計招募600名患者。主要終點將是治療部位的治癒比例達100%的患者比例。兩項研究均在美國舉行。Athenex與美國食品藥物管理局(FDA)在第二期研究結束時曾經就本計劃舉行會議。Athenex預計在8個月內完成第III期研究的招募工作。 KX-01第III期臨床試驗啟動,代表Athenex的第二款新藥物產品進入第III期臨床開發階段,清楚反映Athenex的研究平台實力及研發中藥物的重心。 Athenex, Inc.簡介 Athenex, Inc.成立於2003年,是一家全球性的臨床階段生物醫藥公司,致力於成為開發及發展新一代癌症治療藥物的領導者。Athenex的組織以三大平台為核心,包括腫瘤學創新平台、商業平台與全球供應鏈平台。Athenex的腫瘤學創新平台創造出許多臨床候選藥物,因為其善用了對於激酶的深入了解,包括全新結合位點和人體吸收生理學,並應用了Athenex專屬的研究和實驗室的選擇流程。該公司目前的臨床產品陣容來自兩大不同平台技術,Athenex稱之為「Orascovery」和「Src 激酶抑制」。Orascovery 平台的基礎是新型口服P-gp泵抑製劑分子HM30181A... Read More →
Gemalto ajuda bancos e emissores de meios de pagamento a simplificar e agilizar operações de criptografia
/
Date26 Sep 2017
Nova funcionalidade de particionamento do HSM SafeNet Luna EFT Payment permite que a indústria financeira proteja uma ampla gama de aplicativos de pagamento e transações... Read More →